• Explore /
  • Poster
  • / Tissue-agnostic efficacy of trastuzumab deruxtecan (T-DXd) in advanced solid tumors with <em>HER2</em> amplification identified by plasma cell-free DNA (cfDNA) testing: Results from a phase 2 basket trial (HERALD/EPOC1806).

Tissue-agnostic efficacy of trastuzumab deruxtecan (T-DXd) in advanced solid tumors with HER2 amplification identified by plasma cell-free DNA (cfDNA) testing: Results from a phase 2 basket trial (HERALD/EPOC1806).

Abstract Poster

Authors

null

Hiroya Taniguchi

Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan

Hiroya Taniguchi , Masataka Yagisawa , Taroh Satoh , Shigenori Kadowaki , Yu Sunakawa , Tomohiro Nishina , Yoshito Komatsu , Taito Esaki , Daisuke Sakai , Ayako Doi , Takeshi Kajiwara , Hiromi Ono , Masatoshi Asano , Nami Hirano , Justin Iver Odegaard , Satoshi Fujii , Shogo Nomura , Akihiro Sato , Takayuki Yoshino , Yoshiaki Nakamura

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Chemotherapy and Antibody-Drug Conjugates

Clinical Trial Registration Number

JapicCTI-194707

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 3014)

DOI

10.1200/JCO.2023.41.16_suppl.3014

Abstract #

3014

Poster Bd #

212

Abstract Disclosures

Similar Posters

First Author: Tomoko Jogo

First Author: Tomoko Jogo

First Author: Sara A. Hurvitz

First Author: Evan Y. Yu